Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebelizumab plus SBRT and low-dose radiotherapy in advanced or metastatic NSCLC
ChiCTR2400085672Phase 2Not yet recruiting
- Sponsor
- 901st Hospital of the People's Liberation Army
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebelizumab in non-small cell lung cancer (NSCLC), sponsored by 901st Hospital of the People's Liberation Army. Primary endpoint: Objective response rate. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
adebelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400085672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085672.